Samsung Biologics

28/08/2026

🌟 Meet Abigail De La Pena Garcia, Director of the AAV Technology Group at Samsung Biologics

As gene therapies continue to advance, challenges in manufacturing consistency, immunogenicity, targeted delivery, and cost remain key barriers to bringing these therapies to more patients.

In this interview, Abigail shares her perspective on how Samsung Biologics is addressing these challenges through robust, high-productivity process platforms, advanced analytical approaches, and innovations in vector engineering—including the development of a Mini Helper vector designed to improve AAV titer yield while reducing cost of goods.

Watch the video to learn more.

Biologics

27/08/2026

삼성바이오로직스, 3조원 규모 유상증자 단행
https://samsungbiologics.com/kr/media/company-news/samsung-biologics-3-trillion-won-rights-offering

#삼성바이오로직스

삼성바이오로직스가 글로벌 톱티어 위탁생산개발기업(CDMO)으로의 도약을 위한 유상증자에 나선다. 삼성바이오로직스는 28일 이사회 결의를 통해 총 3조원 규모의 유상증자를 진행하기로 결정했다고 공시했다.

31/07/2026

🌟 Meet Derrick Katayama, Lead Scientist and Associate Director of CDO Formulation at Samsung Biologics.

From enabling higher-dose delivery to addressing the challenges of complex molecular structures, formulation development continues to expand what's possible in biopharmaceutical innovation.

In this interview, Derrick shares his perspective on the trends driving these changes and how innovative screening strategies—grounded in mechanistic insights and fundamental science—can help address the challenges of next-generation biopharmaceutical development.

Watch the video to learn more.

22/07/2026

삼성바이오로직스, 2분기 매출 1조3,209억원·영업이익 5,864억원 기록

https://samsungbiologics.com/kr/media/company-news/samsung-biologics-reports-second-quarter-2026-financial-results

# DrivenForLife #삼성바이오로직스

삼성바이오로직스(대표이사 존 림)가 23일(목) 공시를 통해 2분기 매출 1조3,209억원, 영업이익 5,864억원을 기록했다고 밝혔다. 2분기 매출은 전년 동기 대비 3,067억원(30%), 영업이익은 1,092억원(23%) 증가했다. 1~4공장의 Full 가동 효과...

19/07/2026

삼성바이오로직스, 국내 바이오업계 최대 규모 M&A 성사🎉

👀👉https://samsungbiologics.com/kr/media/company-news/samsung-biologics-announces-all-cash-offer-to-acquire-polypeptide

#삼성바이오로직스

삼성바이오로직스가 글로벌 펩타이드 CDMO(위탁개발생산) 기업을 인수하며, 글로벌 제약∙바이오 시장에서 비만∙당뇨 치료제의 핵심으로 주목받고 있는 펩타이드(Peptide) 의약품 분야에 본격 진출한다. 삼성바이오로직스는 20일...

03/07/2026

🌟Meet Alexis Santana, PhD, MBA, Director of Organoid Sales at Samsung Biologics.

As the biopharmaceutical industry advances toward increasingly complex modalities such as bispecific antibodies. ADCs. and cell therapies. the need for more predictive and human-relevant research models continues to grow.

Supportina this shift, Alexis works closelv with biopharma partners through patient-derived organoid testing services designed to generate meaningful insights earlier in the development. By helping bridge the translational gap between preclinical research and human outcomes, organoids can enable more informed decision-makina and greater confidence before therapies enter clinical trials

In this interview, Alexis discusses the growing role of organoids, emerging New Approach Methodologies (NAMs), and how these innovations can support a more efficient path from discovery to manufacturing through Samsung Biologics' end-to-end capabilities,
Watch the full video below to learn more.

29/06/2026

Consistency is built into every step of how we operate.
ExellenS" is Samsung Biologics' manufacturing framework for standardization, designed to deliver consistent, scalable, and reliable ex*****on across our global manufacturing network. Through a unified operating model, integrated digital systems, and real-time data integration, we enable seamless technology transfer, predictable outcomes, and accelerated validation.
From site to site, our commitment to operational excellence remains constant, helping to drive continuity for our clients.
Advancing biomanufacturing to bring life- changing medicines to patients worldwide.

26/06/2026

That’s a wrap on BIO International 2026! 🧬

From conversations at our booth to discussions across the convention, it has been a rewarding week of connecting with innovators, partners, and industry leaders from around the world.

We sincerely thank everyone who visited our booth and shared valuable perspectives with us throughout the week.

Every interaction helps us better understand the evolving needs of our clients and the industry, inspiring us to continually strengthen our capabilities and further enhance how we support our clients in developing and manufacturing life-saving medicines.

15/06/2026

삼성바이오로직스, 2026 바이오 인터내셔널 컨벤션 참가

삼성바이오로직스(대표이사 존 림)는 세계 최대 바이오·제약 박람회인 '2026 바이오 인터내셔널 컨벤션(BIO International Convention·바이오 USA)'에 참가한다고 15일(월) 밝혔다. 바이오 인터내셔널 컨벤션은 미국 바이오협회(BIO) ....

02/06/2026

Samsung Biologics is broadening its global manufacturing reach through the Rockville Campus in the U.S. 🌏

As part of our ongoing efforts to enhance client proximity and manufacturing diversification, the Rockville Campus strengthens flexibility and regional connectivity across our global network.

Together, the campuses in Songdo and Rockville will help reinforce supply resilience and support seamless collaboration for partners worldwide.